Status:
COMPLETED
Efficacy and Tolerability of Tadalafil Versus Darifenacin in Management of Ureteric Stent-Related LUTS: Results From a Randomized Crossover Trial
Lead Sponsor:
Ain Shams University
Conditions:
Management of Ureteric Stent Related LUTS and Pain
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
PHASE2
Brief Summary
This randomized, crossover clinical trial evaluated the efficacy and safety of tadalafil compared with darifenacin in managing lower urinary tract symptoms (LUTS) and pain related to indwelling ureter...
Eligibility Criteria
Inclusion
- Age:18-40 years
- Patient with ureteric stent size 6 Fr-26 cm post endoscopic procedure.
Exclusion
- Known prostatic patient with LUTS
- Pregnant or lactating women
- Recurrent urinary tract infection.
- Neurological diseases.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 28 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07206706
Start Date
May 1 2022
End Date
December 28 2022
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospita
Cairo, Cairo Governorate, Egypt, 1151